Date:6/29/2011

Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statem
'/>"/>

SOURCE Verenium Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
2. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
3. Verenium to Present at Upcoming Conferences
4. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
5. Verenium to Present at MDB Capital Groups Bright Lights Conference
6. Verenium Announces Debt Repurchase
7. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
8. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
9. Verenium to Present at Jefferies 11th Global Clean Technology Conference
10. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
11. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference